Terms: = Kidney tumors AND BAP1, DKFZp686N04275, 8314, ENSG00000163930, Q92560, KIAA0272, hucep-6, HUCEP-13, FLJ37180, FLJ35406
194 results:
1. MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level.
Liu Y; Qi L; Ye B; Wang A; Lu J; Qu L; Luo P; Wang L; Jiang A
Cancer Biol Ther; 2024 Dec; 25(1):2345977. PubMed ID: 38659199
[TBL] [Abstract] [Full Text] [Related]
2. The Prevalence and Radiologic Features of Renal Cancers Associated with
Charbel C; Causa Andrieu PI; Soliman M; Woo S; Zheng J; Capanu M; Nikolovski I; Vargas HA; Abusamra M; Carlo MI
Radiol Imaging Cancer; 2024 Mar; 6(2):e230063. PubMed ID: 38456787
[TBL] [Abstract] [Full Text] [Related]
3. The bap1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.
Sato H; Ito T; Hayashi T; Kitano S; Erdjument-Bromage H; Bott MJ; Toyooka S; Zauderer M; Ladanyi M
Oncogene; 2024 Apr; 43(15):1087-1097. PubMed ID: 38383726
[TBL] [Abstract] [Full Text] [Related]
4. Unveiling the hidden role of disulfidptosis in kidney renal clear cell carcinoma: a prognostic signature for personalized treatment.
Ye Y; Zeng S; Hu X
Apoptosis; 2024 Jun; 29(5-6):693-708. PubMed ID: 38296888
[TBL] [Abstract] [Full Text] [Related]
5. Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma.
Jiang Z; Wang J; Dao C; Zhu M; Li Y; Liu F; Zhao Y; Li J; Yang Y; Pan Z
Apoptosis; 2024 Jun; 29(5-6):681-692. PubMed ID: 38281281
[TBL] [Abstract] [Full Text] [Related]
6. bap1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
Yuce TH; Ak G; Metintas S; Dundar E; Roe OD; Panou V; Metintas M
J Cancer Res Clin Oncol; 2024 Jan; 150(2):38. PubMed ID: 38280040
[TBL] [Abstract] [Full Text] [Related]
7. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
[TBL] [Abstract] [Full Text] [Related]
8. Genomic Evolution of Oligometastatic Clear Cell Renal Cell Carcinoma Presenting Two Decades Following Radical Nephrectomy.
Wang R; Uzzo N; Chelluri R; Mackrides N; Ehya H; Pei J; Baldwin DA; Wasik MA; Wei S; Uzzo R
Urology; 2024 Feb; 184():79-82. PubMed ID: 38128834
[TBL] [Abstract] [Full Text] [Related]
9. kidney cancer: Links between hereditary syndromes and sporadic tumorigenesis.
Alchoueiry M; Cornejo K; Henske EP
Semin Diagn Pathol; 2024 Jan; 41(1):1-7. PubMed ID: 38008653
[TBL] [Abstract] [Full Text] [Related]
10. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with bap1-mutated clear cell renal cell carcinoma.
Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
[TBL] [Abstract] [Full Text] [Related]
11. Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Lu X; Vano YA; Su X; Helleux A; Lindner V; Mouawad R; Spano JP; Rouprêt M; Compérat E; Verkarre V; Sun CM; Bennamoun M; Lang H; Barthelemy P; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Cell Rep Med; 2023 Nov; 4(11):101287. PubMed ID: 37967556
[TBL] [Abstract] [Full Text] [Related]
12. Functional assay for assessment of pathogenicity of bap1 variants.
Repo PE; Backlund MP; Kivelä TT; Turunen JA
Hum Mol Genet; 2024 Feb; 33(5):426-434. PubMed ID: 37956408
[TBL] [Abstract] [Full Text] [Related]
13. Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.
Kotecha RR; Knezevic A; Arora K; Bandlamudi C; Kuo F; Carlo MI; Fitzgerald KN; Feldman DR; Shah NJ; Reznik E; Hakimi AA; Carrot-Zhang J; Mandelker D; Berger M; Lee CH; Motzer RJ; Voss MH
Cancer; 2024 Mar; 130(5):692-701. PubMed ID: 37864521
[TBL] [Abstract] [Full Text] [Related]
14. A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report.
McLoughlin DE; Chevalier N; Choy E; Cote GM; Gao X; Juric D; Reynolds KL
Oncologist; 2023 Dec; 28(12):1094-1099. PubMed ID: 37844295
[TBL] [Abstract] [Full Text] [Related]
15. Clinical practice guidelines for the diagnosis and surveillance of bap1 tumour predisposition syndrome.
Lalloo F; Kulkarni A; Chau C; Nielsen M; Sheaff M; Steele J; van Doorn R; Wadt K; Hamill M; Torr B; Tischkowitz M; ; Hanson H
Eur J Hum Genet; 2023 Nov; 31(11):1261-1269. PubMed ID: 37607989
[TBL] [Abstract] [Full Text] [Related]
16. Investigating the Role of
Xu S; Hu X; Chong Y; Zhu G
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569676
[TBL] [Abstract] [Full Text] [Related]
17. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
18. Hereditary Renal Cell Carcinoma Syndromes.
Carlo MI
Hematol Oncol Clin North Am; 2023 Oct; 37(5):841-848. PubMed ID: 37258351
[TBL] [Abstract] [Full Text] [Related]
19. Novel genetically engineered mouse models for clear cell renal cell carcinoma.
van der Mijn JC; Laursen KB; Fu L; Khani F; Dow LE; Nowak DG; Chen Q; Gross SS; Nanus DM; Gudas LJ
Sci Rep; 2023 May; 13(1):8246. PubMed ID: 37217526
[TBL] [Abstract] [Full Text] [Related]
20. Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.
Cotta BH; Choueiri TK; Cieslik M; Ghatalia P; Mehra R; Morgan TM; Palapattu GS; Shuch B; Vaishampayan U; Van Allen E; Ari Hakimi A; Salami SS
Eur Urol; 2023 Aug; 84(2):166-175. PubMed ID: 37085424
[TBL] [Abstract] [Full Text] [Related]
[Next]
